This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Modelling
A decision tree was constructed to model pathways of costs and stroke outcomes.
Outcomes assessed in the review
The outcomes assessed in the review were the hazard rate, mortality from stroke, and rate of admission to hospital after stroke.
Study designs and other criteria for inclusion in the review
5 studies included in the review were randomised controlled trials (RCTs).
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
5 RCTs, OCSP study, South of England study, and the Royal College of Physicians report were included.
Methods of combining primary studies

Not stated
Investigation of differences between primary studies
Results of the review
In case 3, hazard rates for stroke of 0.045 for the control group and 0.015 for the warfarin group were used. In case 4, hazard rates for stroke of 0.081 for the control group and 0.012 for the warfarin group were used. In the OCSP study, 30-day and 1-year mortality from stroke were 10% and 31%, respectively. The annual risk of death after the first year was 9.1% up to 5 years.71% of patients were admitted to hospital after stroke in the South of England study compared with 54% in the OCSP study.
